Yusuke Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yusuke Ito has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Yuki Kagoya
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
29 shared publications - Yang Li
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
16 shared publications - Haosong Zhang
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
15 shared publications - Hitomi Kasuya
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
15 shared publications - Satoshi Inoue
Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
15 shared publications - Taeko Hayakawa
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
15 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Phenotypic analysis of WT1-CAR and -TCR T cells upon stimulation by target cells with multiple HLA-II molecules.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Phenotypic analysis of WT1-CAR and -TCR T cells upon stimulation by target cells with multiple HLA-II molecules.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1-TCR and CAR have distinct modes of recognition of WT1 peptide presented with a homologous binding motif across HLA-DP
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1-TCR and CAR have distinct modes of recognition of WT1 peptide presented with a homologous binding motif across HLA-DP
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
HLA-II and WT1 expression of a panel of ALL or AML samples and cell lines.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
HLA-II and WT1 expression of a panel of ALL or AML samples and cell lines.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
In vivo bioluminescent images.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
In vivo bioluminescent images.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Phenotypic analysis of WT1-CAR T cells targeting cells expressing multiple HLA-II molecules.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Phenotypic analysis of WT1-CAR T cells targeting cells expressing multiple HLA-II molecules.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1-specific mAb binds to WT1 peptide presented by HLA-DP molecules.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1-specific mAb binds to WT1 peptide presented by HLA-DP molecules.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1 is presented with a highly conserved motif across HLA- II families.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
WT1 is presented with a highly conserved motif across HLA- II families.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Safety screen of WT1 CAR T cells for cross-reactivity and “on-target, off-tumor” toxicities.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Safety screen of WT1 CAR T cells for cross-reactivity and “on-target, off-tumor” toxicities.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Data from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target lineage-specific surface antigens. However, CAR T cells show limited efficacy against myeloid neoplasms and solid tumors due to challenges in identifying suitable surface targets. In this study, we present a CAR targeting the intracellular WT1 oncoprotein, cross-presented by surface HLA class II (HLA-II) alleles. WT1-CAR T cells, derived from an antibody raised solely against a WT1 peptide, recognized the WT1330–348 peptide promiscuously presented by 18 out of 20 tested HLA-II alleles, overcoming traditional HLA restrictions. WT1-CAR T cells specifically recognized leukemic cells in a WT1- and HLA-II–dependent manner and mediated an antitumor response in vitro and in vivo. This approach broadens CAR-targetable antigens beyond traditional HLA restrictions and offers a promising therapeutic option to a wide and genetically diverse patient population. Significance:Leveraging the promiscuous binding of HLA-II–peptide complexes, we developed a CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families. Our study establishes a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target lineage-specific surface antigens. However, CAR T cells show limited efficacy against myeloid neoplasms and solid tumors due to challenges in identifying suitable surface targets. In this study, we present a CAR targeting the intracellular WT1 oncoprotein, cross-presented by surface HLA class II (HLA-II) alleles. WT1-CAR T cells, derived from an antibody raised solely against a WT1 peptide, recognized the WT1330–348 peptide promiscuously presented by 18 out of 20 tested HLA-II alleles, overcoming traditional HLA restrictions. WT1-CAR T cells specifically recognized leukemic cells in a WT1- and HLA-II–dependent manner and mediated an antitumor response in vitro and in vivo. This approach broadens CAR-targetable antigens beyond traditional HLA restrictions and offers a promising therapeutic option to a wide and genetically diverse patient population. Significance:Leveraging the promiscuous binding of HLA-II–peptide complexes, we developed a CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families. Our study establishes a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.